# Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

> **NCT01010425** · PHASE1 · COMPLETED · sponsor: **Ascendis Pharma A/S** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ACP-001 (TransCon PEG hGH)
- **DRUG:** ACP-001 (TransCon PEG hGH)
- **DRUG:** ACP-001 (TransCon PEG hGH)
- **DRUG:** ACP-001 (TransCon PEG hGH)
- **DRUG:** Placebo
- **DRUG:** Human Growth Hormone

## Key facts

- **NCT ID:** NCT01010425
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2010-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010425, "Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01010425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*